Multicenter phase II trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Multicenter phase II trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer
Authors
Keywords
-
Journal
World Journal of Gastrointestinal Oncology
Volume 10, Issue 12, Pages 505-515
Publisher
Baishideng Publishing Group Inc.
Online
2018-12-14
DOI
10.4251/wjgo.v10.i12.505
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure
- (2017) Noritoshi Kobayashi et al. MEDICINE
- Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer
- (2016) Stacey M Stein et al. BRITISH JOURNAL OF CANCER
- Post-gemcitabine therapy for patients with advanced pancreatic cancer – A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-containing regimens
- (2016) Arndt Vogel et al. CANCER TREATMENT REVIEWS
- Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline
- (2016) Davendra P.S. Sohal et al. JOURNAL OF CLINICAL ONCOLOGY
- PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy
- (2016) Sharlene Gill et al. JOURNAL OF CLINICAL ONCOLOGY
- Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
- (2016) Andrea Wang-Gillam et al. LANCET
- Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2015) M. Ducreux et al. ANNALS OF ONCOLOGY
- Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort
- (2015) Alix Portal et al. BRITISH JOURNAL OF CANCER
- Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials
- (2015) Adnan M. Nagrial et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Safety and Efficacy of Modified FOLFIRINOX for Advanced Pancreatic Adenocarcinoma: A UK Single-Centre Experience
- (2015) Ehsan Ghorani et al. ONCOLOGY
- FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study
- (2014) Aziz Zaanan et al. BMC CANCER
- Phase II clinical trial of ex vivo-expanded cytokine-induced killer cells therapy in advanced pancreatic cancer
- (2014) Moon Jae Chung et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- 5-Fluorouracil/Leucovorin Combined with Irinotecan and Oxaliplatin (FOLFIRINOX) as Second-Line Chemotherapy in Patients with Advanced Pancreatic Cancer Who Have Progressed on Gemcitabine-Based Therapy
- (2014) Min Geun Lee et al. CHEMOTHERAPY
- Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial
- (2014) Helmut Oettle et al. JOURNAL OF CLINICAL ONCOLOGY
- Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials
- (2013) O. E. Rahma et al. ANNALS OF ONCOLOGY
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Modified FOLFIRINOX Regimen With Improved Safety and Maintained Efficacy in Pancreatic Adenocarcinoma
- (2013) Hemchandra Mahaseth et al. PANCREAS
- Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial
- (2012) Sophie Gourgou-Bourgade et al. JOURNAL OF CLINICAL ONCOLOGY
- Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group
- (2011) Uwe Pelzer et al. EUROPEAN JOURNAL OF CANCER
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- 5-Fluorouracil/Leucovorin Combined with Irinotecan and Oxaliplatin (FOLFIRINOX) as Second-Line Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma
- (2011) Elias Assaf et al. ONCOLOGY
- Oxaliplatin, 5-Fluorouracil, and Leucovorin as Second-Line Treatment for Advanced Pancreatic Cancer
- (2010) Anna Novarino et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Irinotecan Plus Bolus/Infusional 5-Fluorouracil and Leucovorin in Patients With Pretreated Advanced Pancreatic Carcinoma
- (2010) Vittorio Gebbia et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Pancreatic Cancer
- (2010) Manuel Hidalgo NEW ENGLAND JOURNAL OF MEDICINE
- A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer
- (2009) C Yoo et al. BRITISH JOURNAL OF CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started